In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.

Conclusions. Continued surveillance of antimicrobial resistance and resistance mechanisms, including the study of imipenem-relebactam as it approaches regulatory approval, appears warranted. PMID: 31976856 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31976856?dopt=Abstract

Source: Journal of Medical Microbiology - January 23, 2020 Category: Microbiology Authors: Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF Tags: J Med Microbiol Source Type: research

More News: Antimicrobial Resistance | Microbiology | Multidrug Resistance | Study | Urinary Tract Infections